Key result
TTVI reduces HF hospitalizations and improves QoL in TR without an established survival benefit.
Why the study?
Although tricuspid regurgitation has substantial adverse prognostic implications, medical therapy is limited and surgery often carries poor outcomes due to late referral, making transcatheter tricuspid valve interventions an emerging therapeutic option requiring optimal management strategies.
TTVI is a valuable therapeutic option for TR that improves symptoms and quality of life, requiring careful patient selection by a multidisciplinary Heart Team.
Supports TTVI as valuable therapy in selected TR patients; leaves open survival benefit pending randomized trials.
Tricuspid regurgitation (TR) has long been underestimated, traditionally viewed as a benign condition, yet contemporary evidence demonstrates its high prevalence and substantial adverse prognostic implications. Medical therapy remains limited, and although surgery has historically been the standard of care, many patients are referred at advanced stages, contributing to poor operative outcomes. Transcatheter tricuspid valve interventions (TTVI) have emerged as a valuable therapeutic option, showing consistent improvements in symptoms, quality of life (QoL), and heart failure hospitalizations (HFH), although a definitive survival benefit has not yet been established. Optimal management requires a comprehensive, multiparametric, and multidisciplinary approach. Key elements include careful assessment of TR etiology, clinical status, right heart failure stage, multimodality imaging, risk scores, and invasive hemodynamics. Integrating these factors enables appropriate patient selection, individualized treatment strategies, and avoidance of futile procedures. Ultimately, decisions regarding intervention and device choice should be guided by a dedicated multidisciplinary Heart Team within a specialized Heart Valve Center.
No takes yet. Share an insight, caveat, or question.
Serafini et al. (2026) studied this question. Transcatheter tricuspid valve interventions improve symptoms, quality of life, and heart failure hospitalizations in tricuspid regurgitation, though a survival benefit is not yet established.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: